Similar Search Results

Cost Effectiveness of Cephalosporin Monotherapy and Aminoglycoside/ Ureidopenicillin Combination Therapy: For the Treatment of Febrile Episodes in Neutropenic Patients

Paladino, Joseph A.; Fong, Debra A.; Forrest, Alan; … - In: PharmacoEconomics 18 (2000) 4, pp. 369-381

utilisation included costs for study antibacterials, treatment of adverse effects and failures, and hospitalisation. The primary …

Persistent link: https://www.econbiz.de/10005590555

Treatment of Pneumonias in a Managed-Care Organisation: The Impact of a Treatment Guideline Promotion on Physician Prescribing Behaviour

Armstrong, Edward P.; Langley, Paul C. - In: Disease Management and Health Outcomes 6 (1999) 3, pp. 159-173

Objective: To evaluate a pneumonia disease management programme in a naturalistic setting. Design and Setting: A 300 … prescribing by physicians. A relational database was created to measure changes in healthcare resources, use of antibacterials and … 2 disease management specialists. Participants: All patients with pneumonia diagnoses on the medical claims database …

Persistent link: https://www.econbiz.de/10005404618

Lower Respiratory Tract Infections: Impact on the Workplace

Birnbaum, Howard G.; Morley, Melissa; Leong, Stephanie; … - In: PharmacoEconomics 21 (2003) 10, pp. 749-759

exacerbations of chronic bronchitis and pneumonia. Data from medical, prescription drug and disability claims of a large, national …

Persistent link: https://www.econbiz.de/10005404783

Economic Aspects of Pneumococcal Pneumonia: A Review of the Literature

De Graeve, Diana; Beutels, Philippe - In: PharmacoEconomics 22 (2004) 11, pp. 719-740

In this review, the economic aspects of pneumococcal pneumonia are analysed, including the costs, cost effectiveness … conducted largely in Europe and the US. Most pertained to community-acquired pneumonia (CAP) in general, without specific … pneumococcal pneumonia are in line with clinical evidence. A drug with proven clinical effectiveness would also appear to be …

Persistent link: https://www.econbiz.de/10005404998

Cost Effectiveness of Ciprofloxacin plus Metronidazole versus Imipenem-Cilastatin in the Treatment of Intra-Abdominal Infections

Walters, Daniel J.; Solomkin, Joseph S.; Paladino, Joseph A. - In: PharmacoEconomics 16 (1999) 5, pp. 551-561

while continuing on active IV antibacterials; their success rate was 94%, mean duration of therapy was 10.1 days and mean …

Persistent link: https://www.econbiz.de/10005243176

Decision Analysis of Histamine H2-Receptor Antagonist Maintenance Therapy Versus Helicobacter pylori Eradication Therapy: A Randomised Controlled Trial in Patients with Continuing...

Tavakoli, Manouche; Prach, Andrzej T.; Malek, Mo; … - In: PharmacoEconomics 16 (1999) 4, pp. 355-365

Background: Much has been published on the efficacy and cost effectiveness of Helicobacter pylori eradication treatment as an alternative to histamine H2-receptor antagonist maintenance treatment in peptic ulcer disease. However, most studies have analysed and emphasised H. pylori eradication...

Persistent link: https://www.econbiz.de/10005243190

Principles of Perioperative Antibacterial Prophylaxis: Management of Surgical Site Infections

Bohnen, John - In: Disease Management and Health Outcomes 6 (1999) 2, pp. 73-81

This article reviews perioperative antibacterial prophylaxis, a discrete in-hospital intervention that prevents surgical site infections and reduces the costs of complications and adverse effects of care. Clinical trials have shown that, when used appropriately, prophylactic antibacterial agents...

Persistent link: https://www.econbiz.de/10005448844

Management of Tuberculosis: Special Considerations

Choi, Chester - In: Disease Management and Health Outcomes 4 (1998) 4, pp. 205-216

The treatment and prevention of tuberculosis have gained importance as the number of cases continues to increase worldwide and the ability of the disease to pass from one area to another becomes progressively greater. Interventions used in the US to help control the disease include the...

Persistent link: https://www.econbiz.de/10005448913

Management of Febrile Episodes in Neutropenic Patients: Defining the Role of Meropenem

Lamb, Harriet M.; Goa, Karen L. - In: Disease Management and Health Outcomes 5 (1999) 2, pp. 101-115

Neutropenic patients with cancer are at risk of serious infection, particularly if neutropenia is severe or prolonged. Because patients with neutropenia have a diminished inflammatory response, fever is sometimes the first, and only, sign of infection. Prompt empirical antibacterial therapy is...

Persistent link: https://www.econbiz.de/10005448947

Counting the Costs of Drug-Related Adverse Events

White, T. Jeffrey; Arakelian, Annet; Rho, Jay P. - In: PharmacoEconomics 15 (1999) 5, pp. 445-458

hospitals, exceeding deaths caused by pneumonia and diabetes. The economic burden resulting from drug-related morbidity and …

Persistent link: https://www.econbiz.de/10005449050